NCT06181734View on ClinicalTrials.gov

Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC

RecruitingOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

June 30, 2028

Study Completion Date

December 30, 2028

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG

Ivosidenib

inhibitor of mutant IDH1

Trial Locations (1)

Unknown

RECRUITING

Praxis für interdisziplinäre Onkologie & Hämatologie, Freiburg im Breisgau

All Listed Sponsors

lead

iOMEDICO AG

INDUSTRY